---
document_datetime: 2026-01-20 15:33:12
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/veyvondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: veyvondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2624878
conversion_datetime: 2026-01-20 20:15:06.445997
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VEYVONDI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.I.b.2 Change in test procedure for active | 06/01/2026                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000318957                     | substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                    |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264863 | C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of haemorrhage in children aged less than 18 years for VEYVONDI, based on results from studies 071102 and SHP677-304. Study 071102 is a phase 3, prospective, multicenter, uncontrolled, open-label clinical study to determine the efficacy, safety, and tolerability of the recombinant von Willebrand factor (rVWF) with or without ADVATE (octocog alfa) in the treatment and control of bleeding episodes, the efficacy and safety of rVWF in elective and emergency surgeries, and the pharmacokinetics (PK) of rVWF in children diagnosed with severe von Willebrand disease (VWD); study SHP677- 304 is a phase 3B, prospective, open-label, uncontrolled, multicenter study on long term | 13/11/2025 | 18/12/2025 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Veyvondi-H-C- 004454-II-EMA/VR/0000264863'. |

<div style=\"page-break-after: always\"></div>

|                                       | pediatric and adult subjects with severe VWD. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 6.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.4, to update the PI in accordance with the latest EMA excipients guideline, and to implement editorial changes to the PI.                                                        |            |            |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| Variation type IA / EMA/VR/0000302605 | This was an application for a group of variations. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.a Change in the name of a supplier of a packaging component. If the information is not needed in the dossier CMDh recommends deletion of this information. - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted | 16/10/2025 | N/A        |
| Variation type II / EMA/VR/0000268774 | This was an application for a variation following a worksharing procedure according                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 25/09/2025 | 18/12/2025 |

<div style=\"page-break-after: always\"></div>

| to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.1.a Qualitative and quantitative composition - B.II.e.1.a.3 Sterile medicinal products and biological/ immunological medicinal products - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|